A 40-year-old patient presented with rapidly progressing peripheral neuropathy secondary to monoclonal gammopathy of unknown significance (MGUS). He became severely debilitated, being wheelchairbound, despite treatment with chemotherapy, intravenous immunoglobulin and plasma exchange. He was subsequently treated with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT). He has made remarkable recovery at 12 months post transplantation. We propose that high-dose chemotherapy and autologous PBSC transplantation may have a role in the treatment of severe, progressive and treatment-resistant MGUS-related peripheral neuropathy.
Five percent of all patients with monoclonal gammopathy of undetermined significance (MGUS) have evidence of peripheral neuropapthy. 1 Although most neuropathy is mild to moderate in severity, some peripheral neuropathies are severe and crippling. The exact pathogenesis of MGUSassociated neuropathy is poorly understood; however, neural-specific antibodies including anti-MAG antibody have been implicated to trigger an immune-mediated injury. Various combinations of plasmapheresis, intravenous immunoglobulin, prednisolone and immunosuppressants have been used with variable success. [1] [2] [3] [4] [5] Nevertheless, a small subgroup of patients remains resistant to treatment.
We report a patient with severe progressive IgG MGUS-associated neuropathy resistant to conventional treatment who subsequently underwent autologous PBSC transplantation. We describe his clinical course, correlating it to his paraprotein levels and nerve conduction studies over a period of 12 months post transplantation.
Case report
A 40-year-old cabinet maker, previously well, presented in September 1998 with a 4 week history of 'coldness' in the feet, general lethargy and night sweats. He was noted to have distal lower limb weakness 4/5 bilaterally with absent reflexes in both upper and lower limbs. Sensory modalities were all intact.
There was no family history of neurological or haematological diseases.
Full blood examination, serum electrolytes, calcium, phosphate, ESR, liver function test, vitamin B12 and folate were normal. Plasma immunoelectrophoresis revealed IgG of 9 g/l (IgG 13.9 g/l, 1gA 2.6 g/l, IgM 1.3 g/l). Urine analysis for Bence-Jones protein was negative. Bone marrow biopsy showed 9% plasma cells with active normal haemopoietic cell lines. Cerebral spinal fluid protein was elevated at 1.33 g/l. CT scan of chest, abdomen and pelvis were normal. MRI of brain and spine only revealed small disc bulges at T7-T8 and L5-S1 levels with no evidence of cord compression. Skeletal survey was essentially normal with no evidence of lytic or sclerotic lesions. Electromyography from September 1998 showed demyelinating neuropathy with superimposed axonal features.
The patient was initially noted to have mild skin pigmentation and although the diagnosis of POEMS syndrome was entertained, hormonal studies including thyroid function tests, diurnal cortisol, LH, FSH and testosterone were all normal. He did not have organomegaly or lymphadenopathy. Based on the clinical features and investigation results, a diagnosis of MGUS-related peripheral neuropathy was made.
The patient was treated with a course of intravenous immunoglobulin (2 mg/kg) and 10 cycles of plasmapharesis without improvement. He subsequently had two courses of VAD (vincristine, adriamycin, dexamethasone) chemotherapy at another institution without clinical or biochemical response. He continued to deteriorate over the next few months, developing profound weakness in both lower limbs grade 0/5-1/5 distally and 3/5 proximally. He was unable to walk without assistance. Proprioception and vibration sense were absent distal to the ankles but pinprick and temperature sensations were preserved. The upper limbs were mildly affected with distal weakness grade 4/5 and proximal weakness grade 4/5. A repeat electromyography in November 1998 showed severe mixed demyelinating and axonal polyneuropathy. His paraprotein level at that stage was 5 g/l.
He was given another course of intravenous immunoglobulin (2 g/kg) without benefit. Further investigations including vasculitic screen (ANA, ANCA, rhematoid factor, ENA) were negative. Hepatitis B, Hepatitis C, HIV, CMV and syphillis serology were negative. Colonic biopsy did not show any evidence of amyloidosis. Sural nerve biopsy showed ellerian degeneration with no evidence of vasculitis or amyloidosis. A repeat skeletal survey was normal.
Given his rapid deterioration he was offered the option of autologous PBSCT. In January 1999, he had a course of high-dose cyclophosphamide followed by peripheral blood stem cell collection. His paraprotein level peaked at 11 g/l just before PBSCT. In March 1999, he received high-dose melphalan 200 mg/m 2 prior to autologous stem cell infusion. The peri-transplant period was complicated by pneumonia and prolonged diarrhoea secondary to bacterial overgrowth.
At 2 months post transplantation, he showed moderate improvement, walking 50 meters with a pick-up walking frame. Bone marrow biopsy showed 1% plasma cells with a plasma paraprotein level of 5 g/l. At 3 months, bone marrow biopsy showed 2% plasma cells and the paraprotein level was 1 g/l. Repeat electromyography showed no further progression of the neuropathy. At 6 months the paraprotein level increased to 4 g/l. At 9 months, he was walking with a single-point stick and was able to use power tools. His upper limb strength returned to 5/5. Hips and knees were both 5/5 in strength but he was not able to dorsi-flex his ankles and toes (0/5). Bone marrow biopsy revealed minimal residual disease (plasma cell Ͻ1%) with a plasma paraprotein level of 2 g/l. At 12 months, he was able to walk without a stick. He had residual distal lower limb weakness with moderate loss of vibration sense and proprioception. Paraprotein level at 12 months was 2 g/l. Figure 1 illustrates the trend of his plasma paraprotein over 12 months post transplant. Figures 2 and 3 depict the improvement in both conduction velocity and amplitude of the left ulnar and median nerves which parallel the patient's clinical recovery.
Discussion
MGUS is a term used to describe the condition in which paraproteins are present in the plasma in the absence of clinical or laboratory evidence of a malignant plasma cell dyscrasia. 6 It was previously termed benign monoclonal gammopathy but this was considered by some authors as misleading because a significant proportion of these patients eventually develop a plasma cell dyscrasia. This was supported by Kyle et al who showed that 26% of 241 patients with MGUS developed a plasma cell dyscrasia over 24-38 years. 6 Among these 26%, 68% had myeloma, 13% had amyloidosis, 11% had Waldenstrom's macroglobulinemia and 8% had other lymphoproliferative diseases. 6 Peripheral neuropathy is well recognised to be associated with malignant plasma cell dyscrasias such as multiple myeloma and Waldenstrom's macroglobulinaemia. The association of peripheral neuropathy and MGUS was established during the early 1970s and 1980s when there were multiple case reports and clinical studies associating monoclonal antibodies with peripheral neuropathy. 7, 8 Direct immunofluorescence was frequently positive in IgM kappaassociated neuropathy, 7 but less so in IgG-and IgA-associated neuropathy. 8 These antibodies were later shown to react with myelin-associated glycoprotein. 8 Between the 1980s and 1990s, a spectrum of antibodies was shown to react with other neural antigens such as GM1 ganglioside, sulphatide and chondroitin sulphate 1 but their pathogenetic role is less clearly established. MGUS-associated neuropathy most commonly presents with mixed motor-sensory polyneuropathy and in about 50% of patients, the clinical and electrophysiological features are those of chronic inflammatory demyelinating neuropathy (CIDP). 1 Of all MGUS, 14% are IgM, 73% IgG and 11% IgA, corresponding to the distribution of the immunoglobulins in normal plasma, 6 however, among patients with MGUS neuropathy, 60% are IgM, 33% IgG and 11% IgA, 1 suggesting that IgM MGUS is more closely associated with peripheral neuropathy compared with IgG and IgA MGUS. 1 It has been shown that 50% of IgM MGUS have antibody activity against myelin-associated glycoprotein 1,6-9 with immunochemical staining of nerves showing widened myelin lamellae corresponding to the distribution of MAG. 1 The treatment of MGUS neuropathy depends on severity. Various combinations of plasmapheresis, intravenous immunoglobulin (IVIG), prednisolone and immunosuppressants (eg chlorambucil, cyclophosphamide) have been used with variable success. [1] [2] [3] [4] [5] Plasmapheresis has previously been shown to be beneficial for peripheral neuropathy associated with plasma cell dyscrasias and chronic inflammatory demyelinating polyneuropathies. 10 A randomised, double-blinded, cross-over trial of 39 patients with MGUS neuropathy showed significant symptomatic improvement in patients treated with plasmapheresis (Dyck et al 10 ). IgG and IgA groups were shown to have a better response to plasmapheresis.
The efficacy of IVIG in the treatment of MGUS neuropathy is controversial. Two open trials with small study samples (Cook et al, 3 Leger et al
showed moderate benefit in patients treated with IVIG. On the other hand, Mariette et al 2 who compared IVIG with interferon-␣ in the treatment of IgM MGUS neuropathy showed a minimal response to IVIG and a significant response to interferon-␣. 2 Notermans et al 5 conducted a prospective study of 16 patients with MGUS neuropathy treated with intermittent cyclophosphamide and prednisone over 6 months. Eight Bone Marrow Transplantation patients had significant improvement, whereas six were stable after 3 years of follow-up.
Rituximab, an anti-CD20 monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, has been used to treat two patients with peripheral neuropathy and anti-MAG IgM gammopathies (Latov et al 11 ). The neuropathy stabilised in one patient and improved in the other.
Hogan et al 12 described a patient with POEMS syndrome who had severe peripheral neuropathy which was successfully treated with myeloablative chemotherapy and autologous PBSCT. The patient progressed from being wheelchairbound to independently ambulant post PBSCT.
There are no reported cases of stem cell transplantation for the treatment of MGUS neuropathy. Rudnicki et al 13 reported a patient with progressive neuropathy and Parkinsonism associated with Waldenstrom's macroglobulinaemia resistant to conventional treatment who subsequently received high-dose melphalan and autologous bone marrow transplantion. The patient had significant improvement in the neuropathy but not the Parkinsonism. 13 Grimes et al . He became neutropenic and was hospitalised. On recovery, his M-band disappeared and he had progressive improvement in his neuropathy.
Interferon, thalidomide and prednisolone are often used as part of maintenance treatment for residual clonal disease. With respect to our patient, we will start him on prednisolone 50 mg on alternate days if his paraprotein level increases. If his disease worsens and his neurological status deteriorates, it would be reasonable to consider a second course of high-dose chemotherapy with or without repeat autologous PBSCT.
In conclusion, MGUS-associated neuropathy can be severe and disabling. Although various neural-specific antibodies have been discovered, the exact pathogenesis of MGUS neuropathy is still not fully understood. We propose that high-dose chemotherapy and autologous stem cell transplantation may have a role in the treatment of severe, progressive and treatment-resistant MGUS neuropathy.
